Audeo Oncology (Audeo Oncology) Inventory-to-Revenue : 0.00 (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Audeo Oncology's Average Total Inventories for the quarter that ended in Sep. 2012 was $0.00 Mil. Audeo Oncology's Revenue for the three months ended in Sep. 2012 was $0.06 Mil. Audeo Oncology's Inventory-to-Revenue for the quarter that ended in Sep. 2012 was 0.00.

Audeo Oncology's Inventory-to-Revenue for the quarter that ended in Sep. 2012 stayed the same from Jun. 2012 (0.00) to Jun. 2012 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Audeo Oncology Inventory-to-Revenue Historical Data

The historical data trend for Audeo Oncology's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Inventory-to-Revenue Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Inventory-to-Revenue

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Inventory-to-Revenue	-	-	-	-

Competitive Comparison of Audeo Oncology's Inventory-to-Revenue

For the Drug Manufacturers - General subindustry, Audeo Oncology's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Inventory-to-Revenue falls into.

Audeo Oncology Inventory-to-Revenue Calculation

Audeo Oncology's Inventory-to-Revenue for the fiscal year that ended in Jun. 2012 is calculated as

	Inventory-to-Revenue (A: Jun. 2012 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Jun. 2011 )	+	Total Inventories (A: Jun. 2012 ))	/	count )	/	Revenue (A: Jun. 2012 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

Audeo Oncology's Inventory-to-Revenue for the quarter that ended in Sep. 2012 is calculated as

	Inventory-to-Revenue (Q: Sep. 2012 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2012 )	+	Total Inventories (Q: Sep. 2012 ))	/	count )	/	Revenue (Q: Sep. 2012 )
=	( (0	+	0)	/	1 )	/	0.061
=	0					/	0.061
=	0.00

Audeo Oncology (DELISTED:AURX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Audeo Oncology's Days Inventory for the three months ended in Sep. 2012 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2012 )	/	Cost of Goods Sold (Q: Sep. 2012 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Audeo Oncology's Inventory Turnover for the quarter that ended in Sep. 2012 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2012 )	/	Average Total Inventories (Q: Sep. 2012 )
	=	0	/	0
	=

Audeo Oncology Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Inventory-to-Revenue

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.